HN2011001247A - Inhibidores de cinana akt y p70 s6 - Google Patents

Inhibidores de cinana akt y p70 s6

Info

Publication number
HN2011001247A
HN2011001247A HN2011001247A HN2011001247A HN2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A
Authority
HN
Honduras
Prior art keywords
inhibitors
cinana
akt
formula
compounds
Prior art date
Application number
HN2011001247A
Other languages
English (en)
Spanish (es)
Inventor
Dean Dally Robert
Joseph Sajan
Alan Shepherd Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001247A publication Critical patent/HN2011001247A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HN2011001247A 2008-11-11 2011-05-03 Inhibidores de cinana akt y p70 s6 HN2011001247A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
HN2011001247A true HN2011001247A (es) 2013-05-20

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001247A HN2011001247A (es) 2008-11-11 2011-05-03 Inhibidores de cinana akt y p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (enExample)
EP (1) EP2358710B1 (enExample)
JP (1) JP5432275B2 (enExample)
KR (1) KR101334460B1 (enExample)
CN (1) CN102216302B (enExample)
AR (1) AR074072A1 (enExample)
AU (1) AU2009314324B2 (enExample)
BR (1) BRPI0921916A2 (enExample)
CA (1) CA2743019C (enExample)
CO (1) CO6382114A2 (enExample)
CR (1) CR20110240A (enExample)
CY (1) CY1113409T1 (enExample)
DK (1) DK2358710T3 (enExample)
DO (1) DOP2011000129A (enExample)
EA (1) EA018947B1 (enExample)
EC (1) ECSP11011048A (enExample)
ES (1) ES2391704T3 (enExample)
HN (1) HN2011001247A (enExample)
HR (1) HRP20120738T1 (enExample)
IL (1) IL211940A (enExample)
JO (1) JO2822B1 (enExample)
MA (1) MA32776B1 (enExample)
MX (1) MX2011005000A (enExample)
MY (1) MY161461A (enExample)
NZ (1) NZ592062A (enExample)
PA (1) PA8846901A1 (enExample)
PE (1) PE20110807A1 (enExample)
PL (1) PL2358710T3 (enExample)
PT (1) PT2358710E (enExample)
RS (1) RS52520B (enExample)
SI (1) SI2358710T1 (enExample)
TN (1) TN2011000207A1 (enExample)
TW (1) TWI422587B (enExample)
UA (1) UA100190C2 (enExample)
WO (1) WO2010056563A1 (enExample)
ZA (1) ZA201102549B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597579A (en) 2009-07-02 2013-06-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
AU2010310786B2 (en) * 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
EA024890B1 (ru) 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
SG2014009260A (en) 2011-09-12 2014-09-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
SI2755965T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Novi imidazolni amidi kot modulatorji kinazne aktivnosti
ES2807539T3 (es) * 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
JP6386467B2 (ja) * 2012-11-16 2018-09-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとしての新規複素環式誘導体
SG11201505999VA (en) * 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
CN105980375A (zh) * 2014-02-11 2016-09-28 默克专利有限公司 用作激酶活性调节剂的嘧啶咪唑胺
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
RU2713181C1 (ru) * 2016-05-20 2020-02-04 Тайхо Фармасьютикал Ко., Лтд. Новое производное 5h-пирроло[2,3-d]пиримидин-6(7h)-она
CN118530260A (zh) 2020-03-17 2024-08-23 江苏恒瑞医药股份有限公司 稠合二环类衍生物、其制备方法及其在医药上的应用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3231865A1 (en) 2021-09-17 2023-03-23 Tingting SHANG Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
MA71401A (fr) * 2022-07-05 2025-04-30 Taiho Pharmaceutical Co., Ltd. 5h-pyrrolo[2,3-d]pyrimidine-6(7h)-one, et cristaux de sel de celui-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
JO2822B1 (en) 2014-09-15
CY1113409T1 (el) 2016-06-22
DOP2011000129A (es) 2016-02-29
TWI422587B (zh) 2014-01-11
JP2012508274A (ja) 2012-04-05
CN102216302B (zh) 2013-08-21
CO6382114A2 (es) 2012-02-15
AU2009314324A1 (en) 2010-05-20
JP5432275B2 (ja) 2014-03-05
HRP20120738T1 (hr) 2012-10-31
PE20110807A1 (es) 2011-10-31
CR20110240A (es) 2011-06-09
PT2358710E (pt) 2012-10-01
KR101334460B1 (ko) 2013-12-02
ECSP11011048A (es) 2011-06-30
EP2358710B1 (en) 2012-08-15
TN2011000207A1 (en) 2012-12-17
DK2358710T3 (da) 2012-09-03
AR074072A1 (es) 2010-12-22
MY161461A (en) 2017-04-14
HK1158203A1 (en) 2012-07-13
CA2743019A1 (en) 2010-05-20
ES2391704T3 (es) 2012-11-29
PL2358710T3 (pl) 2012-12-31
US8148387B2 (en) 2012-04-03
IL211940A (en) 2014-01-30
CN102216302A (zh) 2011-10-12
IL211940A0 (en) 2011-06-30
BRPI0921916A2 (pt) 2015-12-29
WO2010056563A1 (en) 2010-05-20
PA8846901A1 (es) 2010-06-28
AU2009314324B2 (en) 2013-06-20
EP2358710A1 (en) 2011-08-24
SI2358710T1 (sl) 2012-11-30
NZ592062A (en) 2013-03-28
EA018947B1 (ru) 2013-11-29
EA201170680A1 (ru) 2011-12-30
RS52520B (sr) 2013-04-30
ZA201102549B (en) 2012-09-26
US20100120801A1 (en) 2010-05-13
TW201022268A (en) 2010-06-16
MX2011005000A (es) 2011-05-25
CA2743019C (en) 2013-08-13
UA100190C2 (en) 2012-11-26
KR20110074578A (ko) 2011-06-30
MA32776B1 (fr) 2011-11-01

Similar Documents

Publication Publication Date Title
CR20110240A (es) Inhibidores de cinasa akt y p70 s6
ECSP099721A (es) Inhibidores de cinasa p70 s6
CR10782A (es) Compuestos para inhibir la progresion mitotica
CU23774A3 (es) Inhibición de arni de expresión de alfa-enac
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BR112012011328A2 (pt) inibidores de akt
UY33735A (es) Compuestos antivirales
MX2019003738A (es) Compuestos antivirales.
BR112013007362A2 (pt) composição farmacêutica
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
GT200900027A (es) Compuestos organicos
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6321288A2 (es) Sales de compuestos inhibidores de vih
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
GT200600117A (es) Nuevos compuestos farmaceuticos
UY31487A1 (es) Derivados de pirazol como inhibidores de 5-lo